CD33 and acute myeloid leukemia: Meanwhile, novel bifunctional checkpoint-inhibitory T-cell–engaging antibodies that combine CD3- and CD33-bispecific proteins with the extracellular domain of PD-1 have recently been developed and have been reported to improve AML in a mouse xenograft model [76].